66 completed, 7 unknown, 5 terminated, 2 withdrawn. 31 Phase 3, 18 Phase 4, 7 Not applicable, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 28, Unknown 2, Terminated 1 |
| Phase 4 | 18 | Completed 11, Unknown 4, Terminated 3 |
| Not applicable | 7 | Completed 6, Withdrawn 1 |
| Phase 2 | 6 | Completed 4, Terminated 1, Unknown 1 |
Follow this drug Literature Review of Sulfonylurea Compounds trials Research Report on Sulfonylurea Compounds
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antidiabetic Medications and Risk of Cancer Metformin, sulphonylurea, DPP-4 inhibitor - Cancer | Completed | University of Pecs | 74799 | 2025-03-15 | 2026-06-05 | |
| A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs Exenatide, Non-GLP-1 RA based glucose lowering drugs - Pancreatic Cancer | Recruiting | AstraZeneca | 24000 | 2024-09-30 | 2026-09-24 | |
| Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh Omarigliptin, Sulphonylureas, Metformin - Type2diabetes | Phase 4 | Unknown | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | 938 | 2024-09-01 | 2024-07-16 |
| The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients Semaglutide, standard of care - Type 2 Diabetes, Overweight | Phase 4 | Unknown | University Hospital Sestre Milosrdnice | 60 | 2024-02-01 | 2024-02-06 |
| Alter-G Training on Gait and Balance in Diabetic Neuropathy Patients Group- A (100% weight-bearing; n=14), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks., Group- B (70% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks., Group- C (50% weight-bearing), (moderate-intensity (50-70% heart rate reserve) aerobic exercise training on the antigravity treadmill, 3 times/week for 12-weeks. - Diabetic Peripheral Neuropathy | Not applicable | Completed | Umm Al-Qura University | 68 | 2022-01-02 | 2022-10-04 |
| Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor - Type 2 Diabetes, Cardiac Disease | Completed | Mayo Clinic | 386301 | 2021-12-01 | 2025-10-10 | |
| Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas empagliflozin, metformin, sulfonylurea - Diabetes Mellitus, Type 2, Cardiovascular Diseases | Withdrawn | Boehringer Ingelheim | 2021-11-01 | 2022-06-01 | ||
| Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus Liraglutide, Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides - Type 2 Diabetes Mellitus | Phase 3 | Completed | Third Military Medical University | 30 | 2021-01-20 | 2022-05-04 |
| Oral Anti Diabetic Agents in the Hospital Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin - Diabetes Mellitus | Phase 4 | Terminated | Emory University | 85 | 2020-08-07 | 2026-08-31 |
| Dapagliflozin Effect in Cognitive Impairment in Stroke Trial Dapagliflozin 10mg Tab, Statins (Cardiovascular Agents), Platelet Antiaggregant - Stroke, Ischemic, Mild Cognitive Impairment | Phase 2 / Phase 3 | Unknown | Jaime Daniel Mondragon | 270 | 2020-08-01 | 2022-10-04 |
| Study of Sulphonylurea Synergy With DPP4 Inhibitors Sulfonylurea, DPP4 Inhibitor - Type 2 Diabetes | Not applicable | Completed | University of Dundee | 30 | 2019-10-08 | 2021-03-04 |
| Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease Metformin, Sulfonylurea, DPP-4 inhibitor - Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | Completed | Weill Medical College of Cornell University | 4888 | 2019-08-01 | 2023-11-09 | |
| Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes Liraglutide 6 MG/ML Pen Injector, Metformin, Sulfonylurea/non-sulfonylurea insulin secretagogues - Diabetes Mellitus, Type 2 | Phase 3 | Unknown | Cinnagen | 300 | 2019-06-20 | 2019-02-06 |
| Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial Diabetes Medicines, Dapagliflozin - Type 2 Diabetes Mellitus | Phase 4 | Completed | Mackay Memorial Hospital | 76 | 2019-04-01 | 2023-03-22 |
| Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) Sulfonylurea - Permanent Neonatal Diabetes Mellitus | Phase 4 | Unknown | Haukeland University Hospital | 30 | 2019-02-15 | 2020-02-12 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea sotagliflozin (SAR439954), placebo, metformin - Type 2 Diabetes Mellitus | Phase 3 | Terminated | Sanofi | 377 | 2018-11-30 | 2022-04-25 |
| A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease Canagliflozin, Empagliflozin, Dapagliflozin - Diabetes Mellitus, Type 2, Cardiovascular Diseases | Completed | Janssen Research & Development, LLC | 714582 | 2018-02-22 | 2025-06-25 | |
| Replication of the CARMELINA Diabetes Trial in Healthcare Claims Linagliptin, Sulfonylurea - Diabetes | Completed | Brigham and Women's Hospital | 101830 | 2017-09-22 | 2023-07-27 | |
| Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims Saxagliptin, Sulfonylurea - Diabetes | Completed | Brigham and Women's Hospital | 182126 | 2017-09-22 | 2023-08-01 | |
| Replication of the TECOS Diabetes Trial in Healthcare Claims Sitagliptin, Sulfonylurea - Diabetes | Completed | Brigham and Women's Hospital | 349476 | 2017-09-22 | 2023-07-27 |
Showing 20 of 81. Sign in to see all of them.
Diabetes Mellitus, Type 2 (63) · Diabetes Mellitus (20) · Cardiovascular Diseases (4) · Hyperglycemia (4) · Insulin Resistance (3) · Diabetes Mellitus, Permanent Neonatal (2) · Fasting (2) · Heart Diseases (2) · Overweight (2) · Pancreatic Neoplasms (2) · Attention Deficit Disorder with Hyperactivity (1) · Autism Spectrum Disorder (1) · Cognitive Dysfunction (1) · Coronary Disease (1) · Dementia, Vascular (1)
Sanofi (7) · Merck Sharp & Dohme LLC (6) · Eli Lilly and Company (5) · Janssen Research & Development, LLC (5) · Novo Nordisk A/S (4) · Brigham and Women's Hospital (3) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · GlaxoSmithKline (3) · Haukeland University Hospital (3) · Royal Devon and Exeter NHS Foundation Trust (3) · All India Institute of Medical Sciences, Bhubaneswar (2) · Assistance Publique - Hôpitaux de Paris (2) · AstraZeneca (2) · Takeda (2) · Tanabe Pharma Corporation (2)
United States (22) · South Korea (11) · Japan (10) · United Kingdom (10) · India (9) · Canada (8) · France (8) · Norway (8) · Denmark (6) · Germany (6) · Russia (6) · China (5) · Finland (5) · Hungary (5) · Israel (5)
Pierre Ernst, MD, MSc (3) · Shirley Wang, PhD, ScM (3) · Kazuoki Kondo, MD (2) · Takashi Kadowaki, Professor (2) · Alvin Mushlin (1) · Andrew T Hattersley (1) · Andrew T Hattersley, FRCP, DM, BM (1) · Ashraf Abdelaal (1) · Bernard Chaitman, MD (1)
PMID 33327727, PMID 37435938, PMID 16885550, PMID 26579834, PMID 26580237, PMID 27252787, PMID 27977934, PMID 38770818, PMID 39963952, PMID 11372010, PMID 11868855, PMID 15115830, PMID 15448106, PMID 16885549, PMID 17313713, PMID 18025408, PMID 20027034, PMID 20204386, PMID 20380655, PMID 21205123, PMID 21209033, PMID 21444887, PMID 21450987, PMID 21473976, PMID 21562320, PMID 21654091, PMID 21742107, PMID 21768545, PMID 21835316, PMID 21911782, PMID 22496082, PMID 22564709, PMID 22738801, PMID 23008442, PMID 23010561, PMID 23040716, PMID 23410541, PMID 23500245, PMID 23500281, PMID 23564919, PMID 23638466, PMID 23690531, PMID 23735723, PMID 23757426, PMID 23850055, PMID 23857320, PMID 23910429, PMID 24178969, PMID 24397584, PMID 24438170
2015 (2), 2008 (1), 2009 (1), 2014 (1), 2016 (1), K23DK124647 (1), U01DK098246 (1), U01HL061744 (1), U01HL061746 (1), U01HL061748 (1), U01HL063804 (1)